BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a hold rating to a sell rating in a research note issued to investors on Friday morning.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Merus from a hold rating to a buy rating and set a $22.00 price target on the stock in a report on Thursday, September 27th. ValuEngine upgraded shares of Merus from a hold rating to a buy rating in a report on Monday, July 2nd. Finally, Wedbush restated an outperform rating and set a $34.00 price target (up from $26.00) on shares of Merus in a report on Friday, July 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $28.50.
NASDAQ:MRUS traded down $0.32 during trading hours on Friday, hitting $15.71. 14,425 shares of the stock traded hands, compared to its average volume of 45,308. Merus has a fifty-two week low of $14.05 and a fifty-two week high of $26.74. The company has a market cap of $446.61 million, a P/E ratio of -3.66 and a beta of -0.19.
Institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System purchased a new position in shares of Merus during the 2nd quarter valued at $228,000. DRW Securities LLC bought a new stake in Merus in the second quarter worth $286,000. Millennium Management LLC bought a new stake in Merus in the first quarter worth $267,000. Renaissance Technologies LLC boosted its holdings in Merus by 26.8% in the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock worth $1,097,000 after purchasing an additional 10,200 shares in the last quarter. Finally, Stanley Laman Group Ltd. boosted its holdings in Merus by 23.7% in the second quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock worth $1,306,000 after purchasing an additional 10,982 shares in the last quarter. Institutional investors and hedge funds own 54.43% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More: Find a Trading Strategy That Works
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.